Table 3.
Adverse events for withdrawal in SB4 (Benepali®) switchers reported in the studies included in our review
| Adverse events | Number of events(n= 141) |
|---|---|
| Anxiety | 1 (0.7%) |
| Arthralgia | 10 (7%) |
| Bladder dysfunction | 1 (0.7%) |
| Bruising | 2 (1.4%) |
| Chest pain | 4 (2.8%) |
| Coughing | 2 (1.4%) |
| Diarrhea | 4 (2.8%) |
| Dizziness | 5 (3.5%) |
| Dizziness, nausea, headache, loss of appetite | 4 (2.8%) |
| Dyspnea | 3 (2.1%) |
| Erectile dysfunction | 1 (0.7%) |
| Fatigue | 8 (5.7%) |
| Fever | 2 (1.4%) |
| Hair loss | 2 (1.4%) |
| Headache/migraine | 12 (8.5%) |
| Hyperhidrosis | 2 (1.4%) |
| Hypertension | 1 (0.7%) |
| Hypotension | 1 (0.7%) |
| Increased ALT level | 1 (0.7%) |
| Infections | 12 (8.5%) |
| Leg cramps | 2 (1.4%) |
| Leucopenia or neutropenia | 4 (2.8%) |
| Local injection problems | 11 (7.8%) |
| Mood disturbances | 1 (0.7%) |
| Mouth or/and skin ulceration | 2 (1.4%) |
| Myalgia | 3 (2.1%) |
| Nausea | 7 (5%) |
| Neuropathies | 1(0.7%) |
| Palpitations | 2 (1.4%) |
| Paresthesia | 2 (1.4%) |
| Psoriasis worsening or pustulosis | 2 (1.4%) |
| Rash/itching | 22 (15.6%) |
| Uveitis | 1 (0.7%) |
| Visual disturbance | 3 (2.1%) |